Hisato Kawakami

All Stories

1. 
   Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer

   Article • Journal of Clinical Oncology, July 2025, American Society of Clinical Oncology (ASCO)

   Hisato Kawakami

2. 
   Chromosomal Instability Is Associated with cGAS–STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung Cancer

   Article • Cells, March 2025, MDPI AG

   Hisato Kawakami

3. 
   Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01

   Article • Nature Communications, January 2025, Springer Science + Business Media

   Hisato Kawakami

4. 
   Evaluation of immune checkpoint inhibitor efficacy for solid tumors with CD274 (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide database

   Article • Journal for ImmunoTherapy of Cancer, December 2024, BMJ

   Hisato Kawakami

5. 
   Correction: Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)

   Article • Gastric Cancer, November 2024, Springer Science + Business Media

   Hisato Kawakami

6. 
   HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01

   Article • Nature Communications, November 2024, Springer Science + Business Media

   Hisato Kawakami

7. 
   Real-world effectiveness and safety of trastuzumab-deruxtecan in Japanese patients with HER2-positive advanced gastric cancer (EN-DEAVOR study)

   Article • Gastric Cancer, October 2024, Springer Science + Business Media

   Hisato Kawakami

8. 
   QUATTRO-II randomized trial: CAPOXIRI+bevacizumab vs. FOLFOXIRI+bevacizumab as first-line treatment in patients with mCRC

   Article • Med, September 2024, Elsevier

   Hisato Kawakami

9. 
   Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial

   Article • The Lancet Oncology, September 2024, Elsevier

   Hisato Kawakami

10. 
    Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

    Article • Journal of Clinical Oncology, August 2024, American Society of Clinical Oncology (ASCO)

    Hisato Kawakami

11. 
    PD-L1 Immunohistochemistry in Gastric Cancer: Comparison of Combined Positive Score and Tumor Area Positivity Across 28-8, 22C3, and SP263 Assays

    Article • JCO Precision Oncology, July 2024, American Society of Clinical Oncology (ASCO)

    Hisato Kawakami

12. 
    Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

    Article • Nature Medicine, May 2024, Springer Science + Business Media

    Hisato Kawakami

13. 
    Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29‐month follow‐up from a randomized, open‐label, phase III trial

    Article • Cancer Medicine, May 2024, Wiley

    Hisato Kawakami

14. 
    New therapeutic target molecules for gastric and gastroesophageal junction cancer

    Article • International Journal of Clinical Oncology, April 2024, Springer Science + Business Media

    Hisato Kawakami

15. 
    Data from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

    Article • April 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

16. 
    Data from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

    Article • April 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

17. 
    Supplementary Figure S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

    Article • April 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

18. 
    Supplementary Figure S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

    Article • April 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

19. 
    Supplementary Figure S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

    Article • April 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

20. 
    Supplementary Figure S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

    Article • April 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

21. 
    Supplementary Figure S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

    Article • April 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

22. 
    Supplementary Figure S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

    Article • April 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

23. 
    Supplementary Table S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

    Article • April 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

24. 
    Supplementary Table S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

    Article • April 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

25. 
    Supplementary Table S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

    Article • April 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

26. 
    Supplementary Table S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

    Article • April 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

27. 
    Supplementary Table S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

    Article • April 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

28. 
    Supplementary Table S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

    Article • April 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

29. 
    Supplementary Table S4 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

    Article • April 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

30. 
    Supplementary Table S4 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

    Article • April 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

31. 
    Supplementary Table S5 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

    Article • April 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

32. 
    Supplementary Table S5 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

    Article • April 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

33. 
    Anti-integrin αvβ6 autoantibodies are a potential biomarker for ulcerative colitis-like immune checkpoint inhibitor-induced colitis

    Article • British Journal of Cancer, March 2024, Springer Science + Business Media

    Hisato Kawakami

34. 
    Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023

    Article • Gastric Cancer, February 2024, Springer Science + Business Media

    Hisato Kawakami

35. 
    Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer

    Article • ESMO Open, February 2024, Elsevier

    Hisato Kawakami

36. 
    Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

    Article • Clinical Cancer Research, January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

37. 
    Data from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

38. 
    Data from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

39. 
    FIGURE 1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

40. 
    FIGURE 1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

41. 
    FIGURE 2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

42. 
    FIGURE 2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

43. 
    FIGURE 3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

44. 
    FIGURE 3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

45. 
    FIGURE 4 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

46. 
    FIGURE 4 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

47. 
    Supplemental Figure 1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

48. 
    Supplemental Figure 1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

49. 
    Supplemental Figure 2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

50. 
    Supplemental Figure 2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

51. 
    Supplemental Figure 3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

52. 
    Supplemental Figure 3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

53. 
    Supplemental Figure 4 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

54. 
    Supplemental Figure 4 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

55. 
    Supplemental Methods from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

56. 
    Supplemental Methods from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

57. 
    Supplemental Table 1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

58. 
    Supplemental Table 1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

59. 
    Supplemental Table 2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

60. 
    Supplemental Table 2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

61. 
    Supplemental Table 3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

62. 
    Supplemental Table 3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

63. 
    Supplemental Table 4 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

64. 
    Supplemental Table 4 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

65. 
    Supplemental Table 5 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

66. 
    Supplemental Table 5 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

67. 
    TABLE 1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

68. 
    TABLE 1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

69. 
    TABLE 2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

70. 
    TABLE 2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

71. 
    Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Small Cell Lung Cancer Cohort

    Article • Cancer Research Communications, January 2024, American Association for Cancer Research (AACR)

    Hisato Kawakami

72. 
    Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)

    Article • International Journal of Clinical Oncology, January 2024, Springer Science + Business Media

    Hisato Kawakami

73. 
    Exploratory Biomarker Analysis Using Plasma Angiogenesis-Related Factors and Cell-Free DNA in the TRUSTY Study: A Randomized, Phase II/III Study of Trifluridine/Tipiracil Plus Bevacizumab as Second-Line Treatment for Metastatic Colorectal Cancer

    Article • Targeted Oncology, January 2024, Springer Science + Business Media

    Hisato Kawakami

74. 
    The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study

    Article • Frontiers in Immunology, December 2023, Frontiers

    Hisato Kawakami

75. 
    Predictive and prognostic value of excision repair cross-complementing group 1 by multi-omics on the outcomes in patients with advanced gastric cancer

    Article • November 2023, Research Square

    Hisato Kawakami

76. 
    Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G)

    Article • The Oncologist, November 2023, Oxford University Press (OUP)

    Hisato Kawakami

77. 
    Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial

    Article • The Lancet Oncology, November 2023, Elsevier

    Hisato Kawakami

78. 
    Real-World Treatment Sequencing in Vulnerable Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Study

    Article • Targeted Oncology, September 2023, Springer Science + Business Media

    Hisato Kawakami

79. 
    Data from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

80. 
    Data from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

81. 
    Figure S1 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

82. 
    Figure S1 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

83. 
    Figure S2 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

84. 
    Figure S2 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

85. 
    Figure S3 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

86. 
    Figure S3 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

87. 
    Figure S4 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

88. 
    Figure S4 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

89. 
    Figure S5 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

90. 
    Figure S5 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

91. 
    Figure S6 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

92. 
    Figure S6 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

93. 
    Figure S7 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

94. 
    Figure S7 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

95. 
    Figure S8 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

96. 
    Figure S8 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

97. 
    Table S1 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

98. 
    Table S1 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

99. 
    Table S2 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

    Article • August 2023, American Association for Cancer Research (AACR)

    Hisato Kawakami

100. 
     Table S2 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • August 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

101. 
     Table S3 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • August 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

102. 
     Table S3 from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • August 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

103. 
     Role of plasma angiogenesis factors in the efficacy of first‐line chemotherapy combined with biologics in RAS wild‐type metastatic colorectal cancer: Results from the GI‐SCREEN CRC‐Ukit study

     Article • Cancer Medicine, August 2023, Wiley

     Hisato Kawakami

104. 
     Meta-analysis of three randomized trials of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as first-line treatment for advanced gastric cancer

     Article • International Journal of Clinical Oncology, August 2023, Springer Science + Business Media

     Hisato Kawakami

105. 
     Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G)

     Article • BMC Cancer, August 2023, Springer Science + Business Media

     Hisato Kawakami

106. 
     Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)

     Article • British Journal of Cancer, August 2023, Springer Science + Business Media

     Yasuo Hamamoto, Hisato Kawakami

107. 
     Phase I dose-escalation study on irinotecan, cisplatin, and S-1 combination in chemotherapy-naïve patients with HER2-negative advanced gastric cancer (HERBIS-4B, OGSG 1106)

     Article • International Journal of Clinical Oncology, July 2023, Springer Science + Business Media

     Hisato Kawakami

108. 
     Survival impact of microsatellite instability in stage II gastric cancer patients who received S-1 adjuvant monotherapy after curative resection

     Article • Scientific Reports, July 2023, Springer Science + Business Media

     Hisato Kawakami

109. 
     Effect of the number of cycles of docetaxel + S-1 therapy on long-term survival in adjuvant chemotherapy for stage III gastric cancer. A pooled analysis of the OGSG0604 and OGSG1002 trials

     Article • Gastric Cancer, June 2023, Springer Science + Business Media

     Hisato Kawakami

110. 
     Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer

     Article • Nature Communications, June 2023, Springer Science + Business Media

     Hisato Kawakami

111. 
     Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first‐line platinum‐based chemotherapy: Phase 2 study results

     Article • Cancer Medicine, June 2023, Wiley

     Hisato Kawakami

112. 
     Randomised Phase II Trial of Trifluridine/tipiracil (FTD/TPI) plus Ramucirumab (RAM) versus Trifluridine/tipiracil for Previously treated Patients with Advanced Gastric or Esophagogastric Junction Adenocarcinoma (RETRIEVE study, WJOG15822G)

     Article • May 2023, Research Square

     Hisato Kawakami

113. 
     Soluble programmed cell death ligand 1 predicts prognosis for gastric cancer patients treated with nivolumab: Blood-based biomarker analysis for the DELIVER trial

     Article • European Journal of Cancer, May 2023, Elsevier

     Hisato Kawakami

114. 
     A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial

     Article • Targeted Oncology, May 2023, Springer Science + Business Media

     Hisato Kawakami

115. 
     Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer

     Article • Journal of Gastrointestinal Cancer, April 2023, Springer Science + Business Media

     Hisato Kawakami

116. 
     The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy

     Article • Scientific Reports, April 2023, Springer Science + Business Media

     Hisato Kawakami

117. 
     Data from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

118. 
     Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

119. 
     Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

120. 
     Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

121. 
     Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

122. 
     Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

123. 
     Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

124. 
     Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

125. 
     Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

126. 
     Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

127. 
     Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

128. 
     Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

129. 
     Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

130. 
     Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

131. 
     Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

132. 
     Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

133. 
     Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

134. 
     Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

135. 
     Supplementary Data from KRAS Inhibitor Resistance in <i>MET</i>-Amplified <i>KRAS</i><sup>G12C</sup> Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

136. 
     Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

137. 
     Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

138. 
     Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

139. 
     Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

140. 
     Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

141. 
     Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

142. 
     Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

143. 
     Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

144. 
     Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

145. 
     Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

146. 
     Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

147. 
     Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

148. 
     Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

149. 
     Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

150. 
     Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

151. 
     Supplementary Figure from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

152. 
     Supplementary Table from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

153. 
     Supplementary Table from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

154. 
     Supplementary Table from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

155. 
     Supplementary Table from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

156. 
     Supplementary Table from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

157. 
     Supplementary Table from HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • March 2023, American Association for Cancer Research (AACR)

     Hisato Kawakami

158. 
     Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial

     Article • British Journal of Cancer, March 2023, Springer Science + Business Media

     Hisato Kawakami

159. 
     Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial

     Article • Journal of Clinical Oncology, February 2023, American Society of Clinical Oncology (ASCO)

     Hisato Kawakami

160. 
     The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy

     Article • January 2023, Research Square

     Hisato Kawakami

161. 
     Correction: Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma

     Article • Esophagus, January 2023, Springer Science + Business Media

     Hisato Kawakami

162. 
     Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma

     Article • Esophagus, December 2022, Springer Science + Business Media

     Hisato Kawakami

163. 
     TRESBIEN (OGSG 2101): encorafenib, binimetinib and cetuximab for early recurrent stage II/III BRAF V600E-mutated colorectal cancer

     Article • Future Oncology, December 2022, Taylor & Francis

     Hisato Kawakami

164. 
     Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non–small cell lung cancer: A multiplex immunohistochemistry–based single-cell analysis

     Article • Lung Cancer, December 2022, Elsevier

     Hisato Kawakami

165. 
     First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50)

     Article • Esophagus, November 2022, Springer Science + Business Media

     Hisato Kawakami

166. 
     Histology Classification Highlights Differences in Efficacy of S-1 versus Capecitabine, in Combination with Cisplatin, for HER2-Negative Unresectable Advanced or Recurrent Gastric Cancer with Measurable Disease

     Article • Cancers, November 2022, MDPI AG

     Hisato Kawakami

167. 
     Oral formulation of bendamustine hydrochloride for patients with advanced solid tumors; a phase 1 study

     Article • Investigational New Drugs, November 2022, Springer Science + Business Media

     Hisato Kawakami

168. 
     Contribution of MMP14-expressing cancer-associated fibroblasts in the tumor immune microenvironment to progression of colorectal cancer

     Article • Frontiers in Oncology, August 2022, Frontiers

     Hisato Kawakami

169. 
     The Phase II Study of Panitumumab in Chemotherapy-Naïve Frail or Elderly Patients with RAS Wild-type Colorectal Cancer: OGSG 1602 Final Results

     Article • The Oncologist, August 2022, Oxford University Press (OUP)

     Hisato Kawakami

170. 
     Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study

     Article • BMC Cancer, July 2022, Springer Science + Business Media

     Hisato Kawakami

171. 
     Protocol of OGSG 1901: a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S − 1 therapy

     Article • BMC Cancer, July 2022, Springer Science + Business Media

     Hisato Kawakami

172. 
     Phase IIb study of pembrolizumab combined with S‐1 + oxaliplatin or S‐1 + cisplatin as first‐line chemotherapy for gastric cancer

     Article • Cancer Science, July 2022, Wiley

     Hisato Kawakami

173. 
     A phase II study of S-1 therapy for patients with advanced and recurrent esophageal cancer resistant or intolerable to fluorouracil, platinum, and taxane therapy (OGSG 1404)

     Article • Esophagus, June 2022, Springer Science + Business Media

     Hisato Kawakami

174. 
     NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN)

     Article • Journal of Cancer Research and Clinical Oncology, May 2022, Springer Science + Business Media

     Hisato Kawakami

175. 
     Three-Year Outcomes of a Phase II Study of Perioperative Capecitabine Plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601)

     Article • The Oncologist, April 2022, Oxford University Press (OUP)

     Hisato Kawakami

176. 
     NOTCH gene alterations in metastatic colorectal cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN)

     Article • March 2022, Springer Science + Business Media

     Hisato Kawakami

177. 
     Sequential treatment strategy using fluoropyrimidine plus bevacizumab followed by oxaliplatin for metastatic colorectal cancer: A phase II study (OGSG 1107)

     Article • Gastrointestinal Tumors, February 2022, Karger Publishers

     Hisato Kawakami

178. 
     Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

     Article • New England Journal of Medicine, February 2022, New England Journal of Medicine (NEJM/MMS)

     Hisato Kawakami

179. 
     Correction: KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

     Article • Clinical Cancer Research, January 2022, American Association for Cancer Research (AACR)

     Hisato Kawakami

180. 
     HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non–Small Cell Lung Cancer

     Article • Clinical Cancer Research, December 2021, American Association for Cancer Research (AACR)

     Hisato Kawakami

181. 
     Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181

     Article • Esophagus, September 2021, Springer Science + Business Media

     Hisato Kawakami

182. 
     Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinum-based chemotherapy: OGSG1201

     Article • European Journal of Cancer, September 2021, Elsevier

     Hisato Kawakami

183. 
     Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 for advanced gastric cancer that is refractory to S-1 or S-1 plus CDDP: OGSG0701

     Article • International Journal of Clinical Oncology, August 2021, Springer Science + Business Media

     Hisato Kawakami

184. 
     Real-world effectiveness of nivolumab in advanced gastric cancer: the DELIVER trial (JACCRO GC-08)

     Article • Gastric Cancer, August 2021, Springer Science + Business Media

     Hisato Kawakami

185. 
     KRAS Inhibitor Resistance in MET-Amplified KRASG12C Non–Small Cell Lung Cancer Induced By RAS- and Non–RAS-Mediated Cell Signaling Mechanisms

     Article • Clinical Cancer Research, August 2021, American Association for Cancer Research (AACR)

     Hisato Kawakami

186. 
     Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy‐induced colitis

     Article • Molecular Oncology, July 2021, Wiley

     Hisato Kawakami, Dr. Marco A. De Velasco

187. 
     Effects of an oral elemental nutritional supplement in gastric cancer patients with adjuvant S‐1 chemotherapy after gastrectomy: A multicenter, open‐label, single‐arm, prospective phase II study (OGSG1108)

     Article • Annals of Gastroenterological Surgery, July 2021, Wiley

     Hisato Kawakami

188. 
     Serum lactate dehydrogenase is a predictive biomarker in patients with oropharyngeal cancer undergoing radiotherapy: Retrospective study on predictive factors

     Article • Head & Neck, July 2021, Wiley

     Hisato Kawakami

189. 
     Folate receptor α increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb‐202 in gastric cancer

     Article • Clinical and Translational Medicine, June 2021, Wiley

     Hisato Kawakami

190. 
     Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial

     Article • The Lancet Oncology, June 2021, Elsevier

     Hisato Kawakami

191. 
     An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7)

     Article • Cancers, February 2021, MDPI AG

     Hisato Kawakami

192. 
     Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors

     Article • The Oncologist, January 2021, Oxford University Press (OUP)

     Hisato Kawakami

193. 
     Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, FTD/TPI, with Ramucirumab Murine Version DC101 in a Mouse Syngeneic Cancer Transplantation Model

     Article • Journal of Clinical Medicine, December 2020, MDPI AG

     Hisato Kawakami

194. 
     Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021

     Article • Journal of Hepato-Biliary-Pancreatic Sciences, December 2020, Wiley

     Hisato Kawakami

195. 
     Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts

     Article • British Journal of Cancer, December 2020, Springer Science + Business Media

     Hisato Kawakami

196. 
     FMS‐like tyrosine kinase 3 ( FLT3 ) amplification in patients with metastatic colorectal cancer

     Article • Cancer Science, November 2020, Wiley

     Hisato Kawakami

197. 
     Nivolumab versus chemotherapy in Japanese patients with advanced esophageal squamous cell carcinoma: a subgroup analysis of a multicenter, randomized, open-label, phase 3 trial (ATTRACTION-3)

     Article • Esophagus, November 2020, Springer Science + Business Media

     Yasuo Hamamoto, Hisato Kawakami

198. 
     Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies

     Article • Nature Medicine, October 2020, Springer Science + Business Media

     Hisato Kawakami

199. 
     Phase II Study of Panitumumab Monotherapy in Chemotherapy-Naïve Frail or Elderly Patients with Unresectable RAS Wild-Type Colorectal Cancer: OGSG 1602

     Article • The Oncologist, September 2020, Oxford University Press (OUP)

     Hisato Kawakami

200. 
     Revive Study: a Prospective Observational Study in Chemotherapy After Nivolumab Therapy for Advanced Gastric Cancer

     Article • Future Oncology, September 2020, Taylor & Francis

     Hisato Kawakami

201. 
     A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302)

     Article • International Journal of Clinical Oncology, September 2020, Springer Science + Business Media

     Hisato Kawakami

202. 
     Docetaxel plus S-1 versus cisplatin plus S-1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS-3)

     Article • Gastric Cancer, August 2020, Springer Science + Business Media

     Hisato Kawakami

203. 
     A Case of Pulmonary Tumor Thrombotic Microangiopathy Suggested by the Presence of Tumor Cells in Peripheral Blood

     Article • Case Reports in Oncology, July 2020, Karger Publishers

     Hisato Kawakami

204. 
     Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

     Article • New England Journal of Medicine, June 2020, New England Journal of Medicine (NEJM/MMS)

     Hisato Kawakami

205. 
     Comparison of S-1–cisplatin every 5 weeks with capecitabine-cisplatin every 3 weeks for HER2-negative gastric cancer (recurrent after S-1 adjuvant therapy or chemotherapy-naïve advanced): pooled analysis of HERBIS-2 (OGSG 1103) and HERBIS-4A (OGSG 1105...

     Article • International Journal of Clinical Oncology, June 2020, Springer Science + Business Media

     Hisato Kawakami

206. 
     Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study

     Article • European Journal of Cancer, April 2020, Elsevier

     Hisato Kawakami

207. 
     Phase II study of 5-fluorouracil–leucovorin plus bevacizumab for chemotherapy-naïve older or frail patients with metastatic colorectal cancer (OGSG 0802)

     Article • International Journal of Clinical Oncology, March 2020, Springer Science + Business Media

     Hisato Kawakami

208. 
     Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance

     Article • Cancers, February 2020, MDPI AG

     Hisato Kawakami

209. 
     Glasgow Prognostic Score (GPS) and Tumor Response as Biomarkers of Nivolumab Monotherapy in Third- or Later-line Setting for Advanced Gastric Cancer

     Article • In Vivo, January 2020, International Institute of Anticancer Research

     Hisato Kawakami

210. 
     U3-1402 sensitizes HER3-expressing tumors to PD-1 blockade by immune activation

     Article • Journal of Clinical Investigation, December 2019, American Society for Clinical Investigation

     Hisato Kawakami, Masaaki Miyazawa

211. 
     Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI

     Article • Oncogenesis, September 2019, Springer Science + Business Media

     Hisato Kawakami

212. 
     A Phase II Study of Perioperative Capecitabine plus Oxaliplatin Therapy for Clinical SS/SE N1-3 M0 Gastric Cancer (OGSG 1601)

     Article • The Oncologist, September 2019, Oxford University Press (OUP)

     Hisato Kawakami

213. 
     Clinical and immune profiling for cancer of unknown primary site

     Article • Journal for ImmunoTherapy of Cancer, September 2019, BMJ

     Hisato Kawakami

214. 
     A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing

     Article • Scientific Reports, August 2019, Springer Science + Business Media

     Hisato Kawakami

215. 
     DELIVER (JACCRO GC-08) Trial: Discover Novel Host-Related Immune-Biomarkers for Nivolumab in Advanced Gastric Cancer

     Article • Future Oncology, May 2019, Taylor & Francis

     Hisato Kawakami

216. 
     [fam‐] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification

     Article • International Journal of Cancer, May 2019, Wiley

     Hisato Kawakami

217. 
     Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer

     Article • Cancer Medicine, January 2019, Wiley

     Hisato Kawakami

218. 
     Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

     Article • Annals of Oncology, January 2019, Elsevier

     Hisato Kawakami

219. 
     Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS

     Article • Annals of Oncology, January 2019, Elsevier

     Hisato Kawakami

220. 
     Nivolumab-Induced Hemophilia A Presenting as Gastric Ulcer Bleeding in a Patient With NSCLC

     Article • Journal of Thoracic Oncology, December 2018, Elsevier

     Hisato Kawakami

221. 
     Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer

     Article • Cancer Science, November 2018, Wiley

     Hisato Kawakami

222. 
     Phase II Trial of 5-Fluorouracil, Docetaxel, and Nedaplatin (UDON) Combination Therapy for Recurrent or Metastatic Esophageal Cancer

     Article • The Oncologist, October 2018, Oxford University Press (OUP)

     Hisato Kawakami

223. 
     An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC

     Article • Oncogene, October 2018, Springer Science + Business Media

     Hisato Kawakami

224. 
     Randomized, Open‐Label Phase II Study Comparing Capecitabine‐Cisplatin Every 3 Weeks with S‐1‐Cisplatin Every 5 Weeks in Chemotherapy‐Naïve Patients with HER2‐Negative Advanced Gastric Cancer: OGSG1105, HERBIS‐4A Trial

     Article • The Oncologist, August 2018, Alphamed Press

     Hisato Kawakami

225. 
     Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer

     Article • Investigational New Drugs, April 2018, Springer Science + Business Media

     Hisato Kawakami

226. 
     Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer

     Article • Molecular Cancer Research, March 2018, American Association for Cancer Research (AACR)

     Hisato Kawakami

227. 
     Two-step Intensity-modulated Radiation Therapy for Oropharyngeal Cancer: Initial Clinical Experience and Validation of Clinical Staging

     Article • Anticancer Research, January 2018, International Institute of Anticancer Research

     Hisato Kawakami

228. 
     T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non–Small Cell Lung Cancer

     Article • Molecular Cancer Therapeutics, November 2017, American Association for Cancer Research (AACR)

     Hisato Kawakami

229. 
     Abstract 2173: Targeting CDK1 and MEK/ERK overcome mutant BRAF-mediated apoptosis resistance in human colorectal cancer cells

     Article • Cancer Research, July 2017, American Association for Cancer Research (AACR)

     Hisato Kawakami

230. 
     Clinical evaluation of palliative chemoradiotherapy for metastatic esophageal cancer

     Article • Oncotarget, May 2017, Impact Journals, LLC

     Hisato Kawakami

231. 
     Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer

     Article • Investigational New Drugs, March 2017, Springer Science + Business Media

     Hisato Kawakami

232. 
     Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer

     Article • Molecular Cancer Therapeutics, December 2016, American Association for Cancer Research (AACR)

     Hisato Kawakami

233. 
     Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1

     Article • Oncotarget, October 2016, Impact Journals, LLC

     Hisato Kawakami

234. 
     HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy

     Article • Recent Patents on Anti-Cancer Drug Discovery, August 2016, Bentham Science Publishers

     Hisato Kawakami

235. 
     Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer

     Article • Clinical Gastroenterology and Hepatology, May 2016, Elsevier

     Hisato Kawakami

236. 
     Sa1808 Mutant BRAF (V600E) Phosphorylates MCL-1 to Increase Stability/Expression That Confers Apoptosis Resistance in Colorectal Cancer Cells

     Article • Gastroenterology, April 2016, Elsevier

     Hisato Kawakami

237. 
     Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors

     Article • Investigational New Drugs, March 2016, Springer Science + Business Media

     Hisato Kawakami

238. 
     MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy

     Article • Gastric Cancer, December 2015, Springer Science + Business Media

     Hisato Kawakami

239. 
     The Mutant KRAS Gene Up-regulates BCL-XL Protein via STAT3 to Confer Apoptosis Resistance That Is Reversed by BIM Protein Induction and BCL-XL Antagonism

     Article • Journal of Biological Chemistry, September 2015, Elsevier

     Hisato Kawakami

240. 
     Phase I trial of 5-FU, docetaxel, and nedaplatin (UDON) combination therapy for recurrent or metastatic esophageal cancer

     Article • Cancer Chemotherapy and Pharmacology, June 2015, Springer Science + Business Media

     Hisato Kawakami

241. 
     Microsatellite Instability Testing and Its Role in the Management of Colorectal Cancer

     Article • Current Treatment Options in Oncology, June 2015, Springer Science + Business Media

     Hisato Kawakami

242. 
     Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib

     Article • Oncogene, May 2015, Springer Science + Business Media

     Hisato Kawakami

243. 
     49 Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Bcl-xL Antagonism and Induction of Pro-Apoptotic BH3-Only Proteins in Colorectal Carcinoma Cells

     Article • Gastroenterology, April 2015, Elsevier

     Hisato Kawakami

244. 
     Reversal of Mutant KRAS-Mediated Apoptosis Resistance by Concurrent Noxa/Bik Induction and Bcl-2/Bcl-xL Antagonism in Colon Cancer Cells

     Article • Molecular Cancer Research, April 2015, American Association for Cancer Research (AACR)

     Hisato Kawakami

245. 
     A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer

     Article • British Journal of Cancer, February 2015, Springer Science + Business Media

     Hisato Kawakami

246. 
     The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells

     Article • Oncotarget, December 2014, Impact Journals, LLC

     Hisato Kawakami

247. 
     Targeting MET Amplification as a New Oncogenic Driver

     Article • Cancers, July 2014, MDPI AG

     Hisato Kawakami

248. 
     Risk Factors for Cisplatin-Induced Nephrotoxicity and Potential of Magnesium Supplementation for Renal Protection

     Article • PLOS One, July 2014, PLOS

     Hisato Kawakami

249. 
     Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer

     Article • Investigational New Drugs, May 2014, Springer Science + Business Media

     Hisato Kawakami

250. 
     Human papillomavirus DNA and p16 expression in J apanese patients with oropharyngeal squamous cell carcinoma

     Article • Cancer Medicine, October 2013, Wiley

     Hisato Kawakami

251. 
     Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer

     Article • European Journal of Cancer, September 2013, Elsevier

     Hisato Kawakami

252. 
     Abstract 4657: MET amplification as a potential therapeutic target in gastric cancer.

     Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

     Hisato Kawakami

253. 
     MET amplification as a potential therapeutic target in gastric cancer

     Article • Oncotarget, November 2012, Impact Journals, LLC

     Hisato Kawakami

254. 
     Phase I trial of OTS11101, an anti‐angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor

     Article • Cancer Science, November 2012, Wiley

     Hisato Kawakami

255. 
     Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy

     Article • Annals of Oncology, November 2012, Elsevier

     Hisato Kawakami

256. 
     Human Epidermal Growth Factor Eyedrops for Cetuximab-Related Filamentary Keratitis

     Article • Journal of Clinical Oncology, August 2011, American Society of Clinical Oncology (ASCO)

     Hisato Kawakami

257. 
     Assessment of therapeutic effects of transcatheter arterial infusion chemotherapy and transcatheter arterial chemoembolization on hepatocellular carcinoma by Sonazoid®-enhanced ultrasonography

     Article • Kanzo, January 2010, Japan Society of Hepatology

     Hisato Kawakami

258. 
     Evaluation of therapeutic response using Sonazoid®-enhanced ultrasonography after radiofrequency ablation of hepatocellular carcinoma: Comparison with dynamic CT

     Article • Kanzo, January 2009, Japan Society of Hepatology

     Hisato Kawakami

259. 
     Proposal of the radicality grading as a criterion for therapeutic effectiveness of RFA against hepatocellular carcinoma, in relation to the local recurrence rate

     Article • Kanzo, January 2008, Japan Society of Hepatology

     Hisato Kawakami

260. 
     Lemierre's Syndrome with Acute Renal Failure

     Article • Nihon Naika Gakkai Zasshi, January 2007, Japanese Society of Internal Medicine

     Hisato Kawakami

261. 
     Corona enhancement may emerge via sinusoidal drainage pathways

     Article • Kanzo, January 2007, Japan Society of Hepatology

     Hisato Kawakami

262. 
     A case of an FNH-like hyperplastic nodule presenting ring enhancement in a peritumoral spared area on single level dynamic CT during hepatic arteriography

     Article • Kanzo, January 2006, Japan Society of Hepatology

     Hisato Kawakami